Life Sciences – Weekly Industry News

Another Roche move against biosimilars: Kadcyla now approved in EU, Posted on Biosilimar News Roche today announced that Kadcyla (trastuzumab emtansine or T-DM1), the latest targeted medicine from its HER2 franchise and its first antibody-drug conjugate, has been approved by the European Commission for people with previously treated HER2-positive advanced breast cancer. Specifically, Kadcyla is indicated as a…